AstraZeneca's Crestor Patents Ruled Invalid in Australia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca's Crestor Patents Ruled Invalid in Australia


ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca's three patents protecting Crestor (rosuvastatin) have been ruled invalid by the Federal Court of Australia. The patents include a formulation patent expiring in 2020, a patent related to the use of rosuvastatin for the treatment of heterozygous familial hypercholesterolemia, which will expire in 2021, and a patent for treating hypercholesterolaemia with an expiry date of 2020. These patents were challenged by Apotex, Watson Pharma, and Ascent Pharma.

AstraZeneca has expressed disappointment in the court’s ruling on the validity of these three patents. The company is, however, committed to defending its intellectual property protecting Crestor in Australia. This decision is being carefully reviewed while AstraZeneca continues to evaluate all legal options at this stage, which could include filing an appeal and seeking to maintain existing preliminary injunctions.

A press release from the company has stated that the decision of the Federal Court only applies in Australia and will have no impact on the validity of Crestor patents in other countries. It also does not affect AstraZeneca’s financial guidance for 2013, which will, in accordance with normal practice, be reviewed in conjunction with the announcement of the company's first quarter financial results on Apr. 25, 2013.

Sales of Crestor in Australia amounted to approximately $350 million in 2012.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here